Musculoskeletal and body composition response to high-dose testosterone with finasteride after chronic incomplete spinal cord injury—a randomized, double-blind, and placebo-controlled pilot study

BackgroundHigh-dose testosterone replacement therapy (TRT), paired with finasteride (type II 5α-reductase inhibitor), improves body composition, muscle strength, and bone mineral density (BMD) in older men, without inducing prostate enlargement—a side effect associated with TRT. Men with spinal cord...

Full description

Saved in:
Bibliographic Details
Main Authors: Dana M. Otzel, Larissa Nichols, Christine F. Conover, Stephen A. Marangi, Jayachandra R. Kura, Dominic K. Iannaccone, David J. Clark, Chris M. Gregory, Christopher F. Sonntag, Anita Wokhlu, Hans K. Ghayee, Michael J. McPhaul, Charles E. Levy, Charles A. Plumlee, Robert B. Sammel, Kevin T. White, Joshua F. Yarrow
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-12-01
Series:Frontiers in Neurology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fneur.2024.1479264/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850105600021626880
author Dana M. Otzel
Dana M. Otzel
Larissa Nichols
Christine F. Conover
Stephen A. Marangi
Jayachandra R. Kura
Dominic K. Iannaccone
David J. Clark
David J. Clark
Chris M. Gregory
Christopher F. Sonntag
Anita Wokhlu
Anita Wokhlu
Hans K. Ghayee
Michael J. McPhaul
Charles E. Levy
Charles A. Plumlee
Charles A. Plumlee
Robert B. Sammel
Robert B. Sammel
Kevin T. White
Joshua F. Yarrow
Joshua F. Yarrow
Joshua F. Yarrow
Joshua F. Yarrow
author_facet Dana M. Otzel
Dana M. Otzel
Larissa Nichols
Christine F. Conover
Stephen A. Marangi
Jayachandra R. Kura
Dominic K. Iannaccone
David J. Clark
David J. Clark
Chris M. Gregory
Christopher F. Sonntag
Anita Wokhlu
Anita Wokhlu
Hans K. Ghayee
Michael J. McPhaul
Charles E. Levy
Charles A. Plumlee
Charles A. Plumlee
Robert B. Sammel
Robert B. Sammel
Kevin T. White
Joshua F. Yarrow
Joshua F. Yarrow
Joshua F. Yarrow
Joshua F. Yarrow
author_sort Dana M. Otzel
collection DOAJ
description BackgroundHigh-dose testosterone replacement therapy (TRT), paired with finasteride (type II 5α-reductase inhibitor), improves body composition, muscle strength, and bone mineral density (BMD) in older men, without inducing prostate enlargement—a side effect associated with TRT. Men with spinal cord injury (SCI) exhibit neuromuscular impairment, muscle atrophy, bone loss, and increased central adiposity, along with low testosterone. However, sparse evidence supports TRT efficacy after SCI.MethodsThis parallel-group, double-blind, placebo-controlled, and randomized clinical trial (RCT) is a pilot study that enrolled men (N = 12) with low to low–normal testosterone and gait impairments after chronic motor-incomplete SCI. Participants received high-dose intramuscular TRT (testosterone-enanthate, 125 mg/week) with finasteride (5 mg/day) vs. vehicle+placebo for 12 months. Change relative to baseline was determined for body composition, musculoskeletal outcomes, and prostate size, with effect sizes calculated between groups using Hedges’ g. Adverse events and feasibility were assessed.ResultsTRT + finasteride consistently increased testosterone (g = 1.16–3.08) and estradiol (g = 0.43–3.48), while concomitantly reducing dihydrotestosterone (g = 0.31–2.27). Very large effect sizes at both 6 and 12 months suggest TRT + finasteride increased whole-body fat-free (lean) mass (+3–4% vs. baseline, g = 2.12–2.14) and knee extensor (KE) whole-muscle cross-sectional area (+8–11% vs. baseline, g = 2.06–2.53) more than vehicle+placebo. Moderate-to-large effect sizes suggest TRT + finasteride increased KE maximal voluntary isometric torque (+15–40% vs. baseline, g = 0.47–1.01) and femoral neck and distal femur BMD from 6 months onward (g = 0.51–1.13), compared with vehicle+placebo, and reduced fat mass 9–14% within the whole-body, trunk, and android (visceral) regions at 12 months (g = 0.77–1.27). TRT + finasteride also produced small effect sizes favoring lesser prostate growth than vehicle+placebo (g = 0.31–0.43). The participant retention, drug compliance, and incidence and severity of adverse events were similar among the groups.ConclusionThese data provide proof-of-concept and rationale for larger RCTs aimed at discerning the impact of TRT + finasteride on body composition, musculoskeletal health, and physical function in men with SCI, along with effect sizes and variance of responses to assist in planning subsequent trials.Clinical trial registrationClinicalTrials.gov, identifier NCT02248701.
format Article
id doaj-art-d22f66dd5bf64f0a9c7525b00e615faf
institution OA Journals
issn 1664-2295
language English
publishDate 2024-12-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Neurology
spelling doaj-art-d22f66dd5bf64f0a9c7525b00e615faf2025-08-20T02:39:02ZengFrontiers Media S.A.Frontiers in Neurology1664-22952024-12-011510.3389/fneur.2024.14792641479264Musculoskeletal and body composition response to high-dose testosterone with finasteride after chronic incomplete spinal cord injury—a randomized, double-blind, and placebo-controlled pilot studyDana M. Otzel0Dana M. Otzel1Larissa Nichols2Christine F. Conover3Stephen A. Marangi4Jayachandra R. Kura5Dominic K. Iannaccone6David J. Clark7David J. Clark8Chris M. Gregory9Christopher F. Sonntag10Anita Wokhlu11Anita Wokhlu12Hans K. Ghayee13Michael J. McPhaul14Charles E. Levy15Charles A. Plumlee16Charles A. Plumlee17Robert B. Sammel18Robert B. Sammel19Kevin T. White20Joshua F. Yarrow21Joshua F. Yarrow22Joshua F. Yarrow23Joshua F. Yarrow24Brain Rehabilitation Research Center, Malcom Randall Department of Veterans Affairs Medical Center, North Florida/South Georgia Veterans Health System, Gainesville, FL, United StatesDepartment of Physiology & Aging, University of Florida College of Medicine, Gainesville, FL, United StatesBrain Rehabilitation Research Center, Malcom Randall Department of Veterans Affairs Medical Center, North Florida/South Georgia Veterans Health System, Gainesville, FL, United StatesBrain Rehabilitation Research Center, Malcom Randall Department of Veterans Affairs Medical Center, North Florida/South Georgia Veterans Health System, Gainesville, FL, United StatesBrain Rehabilitation Research Center, Malcom Randall Department of Veterans Affairs Medical Center, North Florida/South Georgia Veterans Health System, Gainesville, FL, United StatesBrain Rehabilitation Research Center, Malcom Randall Department of Veterans Affairs Medical Center, North Florida/South Georgia Veterans Health System, Gainesville, FL, United StatesBrain Rehabilitation Research Center, Malcom Randall Department of Veterans Affairs Medical Center, North Florida/South Georgia Veterans Health System, Gainesville, FL, United StatesBrain Rehabilitation Research Center, Malcom Randall Department of Veterans Affairs Medical Center, North Florida/South Georgia Veterans Health System, Gainesville, FL, United StatesDepartment of Neurology, University of Florida College of Medicine, Gainesville, FL, United StatesDepartment of Health Sciences and Research, Medical University of South Carolina, Charleston, SC, United StatesDiagnostic Imaging Service – Radiology, Malcom Randall Department of Veterans Affairs Medical Center, North Florida/South Georgia Veterans Health System, Gainesville, FL, United StatesMedical Specialties Service – Cardiology, Malcom Randall Department of Veterans Affairs Medical Center, North Florida/South Georgia Veterans Health System, Gainesville, FL, United StatesDivision of Cardiovascular Medicine, Department of Medicine, University of Florida College of Medicine, Gainesville, FL, United StatesDivision of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Florida College of Medicine, Gainesville, FL, United StatesQuest Diagnostics Nichols Institute, San Juan Capistrano, CA, United States0Physical Medicine and Rehabilitation Service, Malcom Randall Department of Veterans Affairs Medical Center, North Florida/South Georgia Veterans Health System, Gainesville, FL, United States0Physical Medicine and Rehabilitation Service, Malcom Randall Department of Veterans Affairs Medical Center, North Florida/South Georgia Veterans Health System, Gainesville, FL, United States1Spinal Cord Injury Service, Malcom Randall Department of Veterans Affairs Medical Center, North Florida/South Georgia Veterans Health System, Gainesville, FL, United States1Spinal Cord Injury Service, Malcom Randall Department of Veterans Affairs Medical Center, North Florida/South Georgia Veterans Health System, Gainesville, FL, United States2Geriatrics and Extended Care, South Texas Veterans Health Care System, Kerrville, TX, United States3Michael Bilirakis VA Spinal Cord Injury/Disorders Center, James A. Haley Department of Veterans Affairs Medical Center, Tampa, FL, United StatesBrain Rehabilitation Research Center, Malcom Randall Department of Veterans Affairs Medical Center, North Florida/South Georgia Veterans Health System, Gainesville, FL, United StatesDivision of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Florida College of Medicine, Gainesville, FL, United States4Eastern Colorado Geriatrics Research, Education, and Clinical Center, Rocky Mountain Regional Department of Veterans Affairs Medical Center, VA Eastern Colorado Health Care System, Aurora, CO, United States5Division of Geriatric Medicine, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United StatesBackgroundHigh-dose testosterone replacement therapy (TRT), paired with finasteride (type II 5α-reductase inhibitor), improves body composition, muscle strength, and bone mineral density (BMD) in older men, without inducing prostate enlargement—a side effect associated with TRT. Men with spinal cord injury (SCI) exhibit neuromuscular impairment, muscle atrophy, bone loss, and increased central adiposity, along with low testosterone. However, sparse evidence supports TRT efficacy after SCI.MethodsThis parallel-group, double-blind, placebo-controlled, and randomized clinical trial (RCT) is a pilot study that enrolled men (N = 12) with low to low–normal testosterone and gait impairments after chronic motor-incomplete SCI. Participants received high-dose intramuscular TRT (testosterone-enanthate, 125 mg/week) with finasteride (5 mg/day) vs. vehicle+placebo for 12 months. Change relative to baseline was determined for body composition, musculoskeletal outcomes, and prostate size, with effect sizes calculated between groups using Hedges’ g. Adverse events and feasibility were assessed.ResultsTRT + finasteride consistently increased testosterone (g = 1.16–3.08) and estradiol (g = 0.43–3.48), while concomitantly reducing dihydrotestosterone (g = 0.31–2.27). Very large effect sizes at both 6 and 12 months suggest TRT + finasteride increased whole-body fat-free (lean) mass (+3–4% vs. baseline, g = 2.12–2.14) and knee extensor (KE) whole-muscle cross-sectional area (+8–11% vs. baseline, g = 2.06–2.53) more than vehicle+placebo. Moderate-to-large effect sizes suggest TRT + finasteride increased KE maximal voluntary isometric torque (+15–40% vs. baseline, g = 0.47–1.01) and femoral neck and distal femur BMD from 6 months onward (g = 0.51–1.13), compared with vehicle+placebo, and reduced fat mass 9–14% within the whole-body, trunk, and android (visceral) regions at 12 months (g = 0.77–1.27). TRT + finasteride also produced small effect sizes favoring lesser prostate growth than vehicle+placebo (g = 0.31–0.43). The participant retention, drug compliance, and incidence and severity of adverse events were similar among the groups.ConclusionThese data provide proof-of-concept and rationale for larger RCTs aimed at discerning the impact of TRT + finasteride on body composition, musculoskeletal health, and physical function in men with SCI, along with effect sizes and variance of responses to assist in planning subsequent trials.Clinical trial registrationClinicalTrials.gov, identifier NCT02248701.https://www.frontiersin.org/articles/10.3389/fneur.2024.1479264/fullandrogenestrogentestosterone replacementhypogonadismspinal cord injurymuscle
spellingShingle Dana M. Otzel
Dana M. Otzel
Larissa Nichols
Christine F. Conover
Stephen A. Marangi
Jayachandra R. Kura
Dominic K. Iannaccone
David J. Clark
David J. Clark
Chris M. Gregory
Christopher F. Sonntag
Anita Wokhlu
Anita Wokhlu
Hans K. Ghayee
Michael J. McPhaul
Charles E. Levy
Charles A. Plumlee
Charles A. Plumlee
Robert B. Sammel
Robert B. Sammel
Kevin T. White
Joshua F. Yarrow
Joshua F. Yarrow
Joshua F. Yarrow
Joshua F. Yarrow
Musculoskeletal and body composition response to high-dose testosterone with finasteride after chronic incomplete spinal cord injury—a randomized, double-blind, and placebo-controlled pilot study
Frontiers in Neurology
androgen
estrogen
testosterone replacement
hypogonadism
spinal cord injury
muscle
title Musculoskeletal and body composition response to high-dose testosterone with finasteride after chronic incomplete spinal cord injury—a randomized, double-blind, and placebo-controlled pilot study
title_full Musculoskeletal and body composition response to high-dose testosterone with finasteride after chronic incomplete spinal cord injury—a randomized, double-blind, and placebo-controlled pilot study
title_fullStr Musculoskeletal and body composition response to high-dose testosterone with finasteride after chronic incomplete spinal cord injury—a randomized, double-blind, and placebo-controlled pilot study
title_full_unstemmed Musculoskeletal and body composition response to high-dose testosterone with finasteride after chronic incomplete spinal cord injury—a randomized, double-blind, and placebo-controlled pilot study
title_short Musculoskeletal and body composition response to high-dose testosterone with finasteride after chronic incomplete spinal cord injury—a randomized, double-blind, and placebo-controlled pilot study
title_sort musculoskeletal and body composition response to high dose testosterone with finasteride after chronic incomplete spinal cord injury a randomized double blind and placebo controlled pilot study
topic androgen
estrogen
testosterone replacement
hypogonadism
spinal cord injury
muscle
url https://www.frontiersin.org/articles/10.3389/fneur.2024.1479264/full
work_keys_str_mv AT danamotzel musculoskeletalandbodycompositionresponsetohighdosetestosteronewithfinasterideafterchronicincompletespinalcordinjuryarandomizeddoubleblindandplacebocontrolledpilotstudy
AT danamotzel musculoskeletalandbodycompositionresponsetohighdosetestosteronewithfinasterideafterchronicincompletespinalcordinjuryarandomizeddoubleblindandplacebocontrolledpilotstudy
AT larissanichols musculoskeletalandbodycompositionresponsetohighdosetestosteronewithfinasterideafterchronicincompletespinalcordinjuryarandomizeddoubleblindandplacebocontrolledpilotstudy
AT christinefconover musculoskeletalandbodycompositionresponsetohighdosetestosteronewithfinasterideafterchronicincompletespinalcordinjuryarandomizeddoubleblindandplacebocontrolledpilotstudy
AT stephenamarangi musculoskeletalandbodycompositionresponsetohighdosetestosteronewithfinasterideafterchronicincompletespinalcordinjuryarandomizeddoubleblindandplacebocontrolledpilotstudy
AT jayachandrarkura musculoskeletalandbodycompositionresponsetohighdosetestosteronewithfinasterideafterchronicincompletespinalcordinjuryarandomizeddoubleblindandplacebocontrolledpilotstudy
AT dominickiannaccone musculoskeletalandbodycompositionresponsetohighdosetestosteronewithfinasterideafterchronicincompletespinalcordinjuryarandomizeddoubleblindandplacebocontrolledpilotstudy
AT davidjclark musculoskeletalandbodycompositionresponsetohighdosetestosteronewithfinasterideafterchronicincompletespinalcordinjuryarandomizeddoubleblindandplacebocontrolledpilotstudy
AT davidjclark musculoskeletalandbodycompositionresponsetohighdosetestosteronewithfinasterideafterchronicincompletespinalcordinjuryarandomizeddoubleblindandplacebocontrolledpilotstudy
AT chrismgregory musculoskeletalandbodycompositionresponsetohighdosetestosteronewithfinasterideafterchronicincompletespinalcordinjuryarandomizeddoubleblindandplacebocontrolledpilotstudy
AT christopherfsonntag musculoskeletalandbodycompositionresponsetohighdosetestosteronewithfinasterideafterchronicincompletespinalcordinjuryarandomizeddoubleblindandplacebocontrolledpilotstudy
AT anitawokhlu musculoskeletalandbodycompositionresponsetohighdosetestosteronewithfinasterideafterchronicincompletespinalcordinjuryarandomizeddoubleblindandplacebocontrolledpilotstudy
AT anitawokhlu musculoskeletalandbodycompositionresponsetohighdosetestosteronewithfinasterideafterchronicincompletespinalcordinjuryarandomizeddoubleblindandplacebocontrolledpilotstudy
AT hanskghayee musculoskeletalandbodycompositionresponsetohighdosetestosteronewithfinasterideafterchronicincompletespinalcordinjuryarandomizeddoubleblindandplacebocontrolledpilotstudy
AT michaeljmcphaul musculoskeletalandbodycompositionresponsetohighdosetestosteronewithfinasterideafterchronicincompletespinalcordinjuryarandomizeddoubleblindandplacebocontrolledpilotstudy
AT charleselevy musculoskeletalandbodycompositionresponsetohighdosetestosteronewithfinasterideafterchronicincompletespinalcordinjuryarandomizeddoubleblindandplacebocontrolledpilotstudy
AT charlesaplumlee musculoskeletalandbodycompositionresponsetohighdosetestosteronewithfinasterideafterchronicincompletespinalcordinjuryarandomizeddoubleblindandplacebocontrolledpilotstudy
AT charlesaplumlee musculoskeletalandbodycompositionresponsetohighdosetestosteronewithfinasterideafterchronicincompletespinalcordinjuryarandomizeddoubleblindandplacebocontrolledpilotstudy
AT robertbsammel musculoskeletalandbodycompositionresponsetohighdosetestosteronewithfinasterideafterchronicincompletespinalcordinjuryarandomizeddoubleblindandplacebocontrolledpilotstudy
AT robertbsammel musculoskeletalandbodycompositionresponsetohighdosetestosteronewithfinasterideafterchronicincompletespinalcordinjuryarandomizeddoubleblindandplacebocontrolledpilotstudy
AT kevintwhite musculoskeletalandbodycompositionresponsetohighdosetestosteronewithfinasterideafterchronicincompletespinalcordinjuryarandomizeddoubleblindandplacebocontrolledpilotstudy
AT joshuafyarrow musculoskeletalandbodycompositionresponsetohighdosetestosteronewithfinasterideafterchronicincompletespinalcordinjuryarandomizeddoubleblindandplacebocontrolledpilotstudy
AT joshuafyarrow musculoskeletalandbodycompositionresponsetohighdosetestosteronewithfinasterideafterchronicincompletespinalcordinjuryarandomizeddoubleblindandplacebocontrolledpilotstudy
AT joshuafyarrow musculoskeletalandbodycompositionresponsetohighdosetestosteronewithfinasterideafterchronicincompletespinalcordinjuryarandomizeddoubleblindandplacebocontrolledpilotstudy
AT joshuafyarrow musculoskeletalandbodycompositionresponsetohighdosetestosteronewithfinasterideafterchronicincompletespinalcordinjuryarandomizeddoubleblindandplacebocontrolledpilotstudy